Adipotide, also called FTPP or prohibitin-targeting peptide-1, is an experimental peptidomimetic designed to cut off the blood supply to white fat tissue. Animal studies in mice and monkeys reported reduced body fat and improved metabolic markers, along with kidney-related safety signals. It is not approved for human use, and published human efficacy data does not exist, so its benefits remain research findings rather than established outcomes.
What Is Adipotide?
Adipotide is a lab-designed peptide that targets the blood vessels feeding white fat tissue. It was developed by academic cancer researchers who were mapping the unique 'zip codes' on blood vessels in different tissues. They found that vessels in white fat carry a protein marker called prohibitin on their surface, and they built a peptide to home in on it.
The molecule has two parts joined together:
- A homing sequence (CKGGRAKDC) that binds prohibitin on fat-tissue blood vessels.
- A cell-disrupting sequence, written as D(KLAKLAK)2, that damages the mitochondria of the cells it enters.
Because it borrows the structure of a peptide but was engineered for a specific job, researchers often call it a peptidomimetic. You'll also see it listed as FTPP (fat-targeted proapoptotic peptide). For a quick reference sheet on the compound, see our adipotide peptide overview. If you're new to the category, start with what peptides are and how they work.
One fact to hold onto from the start: adipotide is a research compound. It is not an approved drug, not a dietary supplement, and not something with a track record of human use.
How Adipotide Works: Starving Fat of Its Blood Supply
Adipotide is designed to destroy the small blood vessels that keep white fat alive, so the fat tissue shrinks and gets reabsorbed. This approach is called vascular targeting, and it came straight out of cancer research, where cutting off a tumor's blood supply is a long-studied strategy.
Here's the sequence researchers proposed:
1. The homing segment circulates and binds to prohibitin on the inner lining (endothelial cells) of white fat's blood vessels. 2. Once inside those cells, the KLAKLAK segment disrupts mitochondrial membranes, triggering programmed cell death (apoptosis). 3. With the vessels damaged, the surrounding fat cells lose their supply of oxygen and nutrients. 4. The body breaks down and reabsorbs the starved fat tissue.
This is a fundamentally different mechanism from most compounds people associate with body composition. It doesn't work through appetite hormones, thyroid signaling, or exercise mimicry. It works by deliberately killing cells, just in a targeted location. That precision is the whole idea, and it's also the source of the biggest safety questions, because no targeting system is perfect and the cell-killing segment does not distinguish between intended and unintended targets once inside a cell.
What Research Has Studied Adipotide For
Adipotide has been studied mainly in animal models of excess body fat, with only early, limited human research. The research history falls into three stages.
Mouse studies (early 2000s). The original work, published in Nature Medicine in 2004, tested the fat-targeting concept in obese mice. Researchers reported that the peptide homed to fat vasculature and that treated mice lost fat mass, which established the proof of concept.
Primate study (2011). A study published in Science Translational Medicine tested adipotide in obese rhesus monkeys, which are metabolically much closer to humans than mice. Researchers reported reductions in body weight and fat, along with improvements in insulin-related markers. This study drew wide media attention because it was the first evidence in primates.
Human research (limited). Following the primate work, an early-phase human safety study was planned in a cancer setting, consistent with the compound's oncology origins. To date, there are no published, peer-reviewed human trials demonstrating that adipotide is safe or effective for changing body composition in people.
The takeaway: the research is genuinely interesting, scientifically creative, and well-designed for what it is, but it stops short of the human evidence anyone would need to call these 'benefits' established.
The Reported Benefits in Animal Studies
In animals, adipotide was associated with reduced fat mass, lower body weight, and improved insulin sensitivity markers. These are the findings most often repeated online as 'adipotide benefits.' Here is what each actually means.
- Fat mass reduction. Both mouse and monkey studies reported loss of white fat. This is the direct, expected result of the mechanism.
- Body weight reduction. Weight dropped alongside fat. In the primate study, researchers also noted that food intake decreased, which complicates how much of the effect came from the vascular mechanism alone.
- Metabolic markers. Monkeys showed improvements in measures related to insulin response. Researchers studied this as a possible secondary effect of reduced fat tissue.
What these findings do not tell you:
- Whether the effects would occur in humans at tolerable levels.
- Whether results persist after stopping, or how the body adapts long term.
- How it compares to diet, exercise, or anything else, since those comparisons weren't the point of the research.
Animal results are where research starts, not where it ends. Many compounds that perform well in primates never succeed in human trials. Treat these findings as reasons the scientific community was interested, not as promises of what the compound does for a person.
Safety Signals and Open Questions
The most important safety signal in adipotide research involves the kidneys. In the primate study, researchers observed dose-dependent changes in kidney function and kidney tubule cells. These changes were reported to be reversible after stopping, but they were significant enough to shape how the compound was discussed afterward.
Why this matters: the KLAKLAK segment kills cells by disrupting mitochondria. If the peptide accumulates or gets taken up by cells outside fat-tissue vasculature, such as in the kidneys, which filter small molecules from the blood, those cells can be affected too. Precision targeting reduces off-target effects; it does not eliminate them.
Other open questions researchers have not resolved in humans:
- Dehydration and fluid balance, which were noted in animal work.
- Long-term effects of repeatedly destroying blood vessels in fat tissue.
- Interactions with other compounds, medications, or health conditions.
- Purity and identity of products sold online as 'research peptides,' which have no regulatory oversight for human consumption.
This is why we're direct about it: anyone considering an unapproved compound like adipotide is taking on unknown risk. A qualified healthcare provider is the right person to talk to about any question involving body composition or metabolic health.
What the Evidence Does and Doesn't Show
The evidence shows adipotide is a clever, functional research concept in animals; it does not show the compound is safe or effective in humans. Here's a clear side-by-side.
What research supports:
- White fat blood vessels carry a distinct surface marker (prohibitin) that can be targeted.
- A peptide can be engineered to home to that marker.
- In mice and monkeys, this approach was associated with fat loss and improved metabolic markers.
What research does not support:
- Any established benefit in humans.
- A known safe amount, schedule, or duration for people.
- Claims that it 'melts fat' without side effects, a framing common on research-peptide sites.
- Claims that it is superior to other approaches.
When you see adipotide marketed online, check whether the seller distinguishes between animal and human data. Most don't. Honest education means saying plainly that this compound sits at the preclinical stage, and that the gap between a promising primate study and a proven human outcome is large.
How Adipotide Compares to Other Peptides
Adipotide is unusual among peptides because it works by destroying targeted cells rather than signaling them. Most peptides people hear about act as messengers: they bind receptors and nudge the body toward a response. Adipotide is closer to a guided demolition tool.
A quick comparison of categories:
- Signaling peptides (like those studied for appetite or hormone pathways) work by activating receptors.
- Repair-focused peptides such as BPC-157 and TB-500 have been studied for their role in supporting the body's natural tissue recovery processes.
- Bioregulators are short peptides studied for supporting normal function in specific organs and tissues. Our guide on what bioregulators are explains how they differ from larger peptides.
- Vascular-targeting peptides like adipotide are engineered to bind a tissue marker and trigger cell death there.
That difference in mechanism is why adipotide doesn't belong in the same conversation as everyday wellness peptides. Its risk profile, regulatory status, and research stage are all in a different category.
How to Think Clearly About Peptide Claims
Judge any peptide claim by three questions: Is there human data, is the product verified, and is the language honest? These filters cut through most of the noise in the peptide space.
1. Human data. Ask whether the claim rests on cell, animal, or human research. For adipotide, it's animal research. 2. Verification. Ask who made it, where, and whether each batch is tested by an independent lab. Research-peptide vendors often can't answer this. 3. Honest language. Be wary of words like 'cures,' 'melts,' or 'guaranteed.' Credible sellers say what research has studied and where it stops.
At Ageless Humans, we hold our own products to that standard. Everything we sell is made in our FDA-registered facility in Carlsbad, California, every lot is third-party lab tested with a Certificate of Analysis (COA), and every order is backed by a 60-day money-back guarantee. We publish encyclopedia entries like this one, including on compounds we don't sell, because informed customers make better decisions.
Frequently asked questions
What is adipotide?+
Adipotide is an experimental peptidomimetic, also called FTPP or prohibitin-targeting peptide-1, developed by cancer researchers. It is designed to bind a marker called prohibitin on blood vessels in white fat and trigger the death of those vessel cells. It is a research compound, not an approved drug or dietary supplement.
What are the benefits of adipotide?+
In mouse and rhesus monkey studies, adipotide was associated with reduced fat mass, lower body weight, and improved insulin-related markers. These findings come from animal research only. No published human trials have established any benefit, so these outcomes remain unproven in people.
Is adipotide safe?+
Adipotide's safety in humans has not been established. In the primate study, researchers observed dose-dependent kidney changes that were reported as reversible after stopping. Because the compound works by killing targeted cells, off-target effects are a central concern, and anyone with questions should consult a qualified healthcare provider.
Has adipotide been tested in humans?+
An early-phase human safety study was planned following the primate research, in a cancer setting consistent with the compound's origins. There are no published, peer-reviewed human trials showing adipotide is safe or effective for body composition. Its evidence base remains preclinical.
How is adipotide different from other peptides like BPC-157?+
Adipotide works by destroying cells in a targeted tissue, while peptides like BPC-157 and TB-500 have been studied for supporting the body's natural recovery processes. Most peptides act as signaling messengers rather than cell-killing agents. That makes adipotide's mechanism, risk profile, and research stage very different.
Does Ageless Humans sell adipotide?+
No. Ageless Humans does not sell adipotide, and this article is purely educational. Ageless Humans makes oral peptide and longevity supplements in its FDA-registered facility in Carlsbad, California, with every lot third-party tested and backed by a 60-day money-back guarantee.
